Solana

Solana CROIC

The Cash Return on Invested Capital (CROIC) of Solana (HSDT) as of Oct 18, 2026 is -20.37 %. In the previous year, Cash Return on Invested Capital (CROIC) was -1,031.37 % — a change of -98.03% (higher).

CROIC

-20.37 %

YoY

-98.03%

Last updated:

Cash Return on Invested Capital (CROIC) of Solana is 2025 -20.37 % . Cash Return on Invested Capital (CROIC) of Solana was 2024 -1,031.37 % . It decreases by -98.03% higher compared to the previous year.

The Solana CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-84.92 USD
Jan 1, 2019
-328.75 USD
Jan 1, 2020
-297.85 USD
Jan 1, 2021
-119.39 USD
Jan 1, 2022
-173.43 USD
Jan 1, 2023
-433.94 USD
Jan 1, 2024
-1,031.37 USD
Jan 1, 2025
-20.37 USD
The Solana CROIC history
YEARCROICYoY
-20.37 %-98.03%
-1,031.37 %+137.67%
-433.94 %+150.21%
-173.43 %+45.26%
-119.39 %-59.92%
-297.85 %-9.40%
-328.75 %+287.13%
-84.92 %-128.20%
301.11 %-184.55%
-356.11 %-25.09%
-475.41 %-99.30%
-68,179.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Solana Co, with ticker HSDT and ISIN US42328V8761, is a health care company based in Newtown, United States. The company has 21 employees and went public on June 27, 2014. Its website is https://heliusmedical.com/. Solana Co operates within the health care sector, focusing on neurological wellness through non-invasive medical technologies. The company develops, licenses, or acquires non-invasive platform technologies designed to enhance the brain's natural healing capabilities. While the source description mentions a product called the portable neuromodulation stimulator (PoNS) device, which is described as a class II medical device in Canada for treating balance deficits related to mild-to-moderate traumatic brain injury, Solana Co's profile does not confirm this product or its specific applications. The company's operations and product details are not elaborated beyond the provided information. Solana Co is headquartered in Newtown, Pennsylvania, and its primary focus remains on neurological wellness within the health care industry. The company's public listing date and employee count are the only financial and operational details available in the provided data. No additional acquisitions, founding year, or specific product names beyond the general description are confirmed in the factual information provided. Solana is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solana stock

Cash Return on Invested Capital (CROIC) of Solana is -20.37 % in 2025.

Cash Return on Invested Capital (CROIC) of Solana changed from -1,031.37 % to -20.37 %, representing a -98.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Solana since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Solana with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Solana

All Key Metrics — Solana